Tech Vs Trialists: The Struggle For Integrated Decentralized Clinical Trial Platforms

The EU’s public-private Trials@Home Consortium examined what it would take to develop the fully integrated, unified digital platforms needed to enhance the implementation of decentralized clinical trials.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: Clinical trial
Current DCT digital platforms have limited functionality and technical capabilities • Source: Shutterstock

The lack of “shared understanding” between technology partners and clinical trialists is slowing progress in delivering the fully integrated, unified digital platforms that are needed to better support the use of decentralized clinical trials (DCTs).

More from Europe

Spanish Health Ministry Targets Efficiency With New Medicine Pricing Rules

 

A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Ozempic & NAION: EU Safety Panel Continues Probe Into Link With Eye Condition

 

The European Medicines Agency says it will take appropriate measures to update the Ozempic’s package leaflet if new evidence arises.

New EU Filings

 

Doxecitine/doxribtimine, UCB’s investigational orphan drug for pediatric and adult patients with thymidine kinase 2 deficiency, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

More from Geography

Off-Label Communications: US FDA Clarifies Safe Harbor For Firm-Generated Presentations

 
• By 

Final guidance on communicating scientific information on unapproved uses (SIUU) allows firm-generated presentations to be based on sources other than reprints, but says communications based on nonscientific content are not protected from enforcement.

Spanish Health Ministry Targets Efficiency With New Medicine Pricing Rules

 

A draft royal decree would pave the way for more transparency in pricing and reimbursement decision-making processes and boost competition to increase the participation of generic medicines.

Japan’s 2025 ‘Off-Year’ Price Cut Stirs Deeper Concerns

 
• By 

Multiple industry groups in Japan warn that a decision to implement an "off-year" drug price revision in April will reverse other recent policy moves to support innovation.